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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for which there is
no cure. Huperzine A (HupA) is a natural inhibitor of acetylcholinesterase (AChE) derived
from the Chinese folk medicine Huperzia serrata (Qian Ceng Ta). It is a licensed anti-AD
drug in China and is available as a nutraceutical in the US. A growing body of evidence has
demonstrated that HupA has multifaceted pharmacological effects. In addition to the symp-
tomatic, cognitive-enhancing effect via inhibition of AChE, a number of recent studies have
reported that this drug has “non-cholinergic” effects on AD. Most important among these
is the protective effect of HupA on neurons against amyloid beta-induced oxidative injury
and mitochondrial dysfunction as well as via the up-regulation of nerve growth factor and
antagonizing N -methyl-D-aspartate receptors. The most recent discovery that HupA may
reduce brain iron accumulation lends further support to the argument that HupA could
serve as a potential disease-modifying agent for AD and also other neurodegenerative
disorders by significantly slowing down the course of neuronal death.
Keywords: huperzine A, Alzheimer’s disease, acetylcholinesterase inhibitor, disease-modifying agent, non-
cholinergic effects
INTRODUCTION
Huperzine A (HupA) is a natural inhibitor of acetylcholinesterase
(AChE) derived from the Chinese folk medicine Huperzia serrata
(Qian Ceng Ta) (Ratia et al., 2013). There is a long history of
using H. serrata as a medicine in China to treat different kinds of
disorders, including bruises, strains, swelling, rheumatism, schiz-
ophrenia, myasthenia gravis, and fever (Skolnick, 1997; Ma et al.,
2007). HupA is a licensed anti-Alzheimer’s disease drug in China
and is available as a nutraceutical in the US (Orhan et al., 2011).
A growing body of evidence has demonstrated that HupA could
effectively reverse or attenuate cognitive deficits in rodents, pri-
mates, and human (Howes and Perry, 2011). A recent systematic
review and meta-analysis of randomized clinical trials concluded
that HupA could improve cognitive function, daily living activity,
and global clinical assessment in patients with Alzheimer’s disease
(AD), with relatively few and mild adverse effects mainly related to
its effect on the cholinergic system (Xing, 2014; Yang et al., 2014).
Currently, the pharmacological mechanisms of HupA in the
treatment of AD have not been fully detailed. However, a number
of recent studies have reported that this drug has“non-cholinergic”
effects on AD (Ratia et al., 2013; Huang et al., 2014) in addition
to the symptomatic, cognitive-enhancing effect of cholinesterase
Abbreviations: Aβ, amyloid-β peptide; AChE, acetylcholinesterase; AD, Alzheimer’s
disease; APP, amyloid precursor protein; APP/PS1, APPswe/PS1dE9; ATP, adenosine
5’-triphosphate; BFCNs, basal forebrain cholinergic neurons; CAT, catalase; GSH-
Px, glutathione peroxidase; GSK-3, glycogen synthase kinase-3; H2O2, hydrogen
peroxide; HupA, huperzine A; MDA, malondialdehyde; NFTs, neurofibrillary tan-
gles; NGF, nerve growth factor; NMDA,N -methyl-d-aspartate; PKC, protein kinase
C; ROS, reactive oxygen species; SOD, superoxide dismutase; TBI, transferrin-bound
iron; TfR1, transferrin receptor 1; TrkA, tropomyosin kinase receptor A.
inhibition (Wang et al., 1986; Liu and Liu, 1995; Zhu and Gia-
cobini, 1995). These new findings have greatly improved our
understanding of pharmacological mechanisms of HupA in the
treatment of AD. This article focuses on the recent advances in the
studies on “non-cholinergic” roles of HupA. The updated under-
standing of the “cholinergic” action of HupA has recently been
well-reviewed elsewhere (Fu and Li, 2011; Howes and Perry, 2011).
SENILE PLAQUES AND NEUROFIBRILLARY TANGLES:
CONSEQUENCES RATHER THAN INITIAL EVENTS
Alzheimer’s disease is a progressive neurological disorder clinically
characterized by memory loss, mental deterioration, and impair-
ment in the activities of daily living and behavioral disturbances
throughout the disease course. The senile plaques and neurofib-
rillary tangles (NFTs), which are composed of self-polymerized
amyloid-β peptide (Aβ) and hyperphosphorylated tau proteins,
respectively, are the two major pathological hallmarks in AD brains
(Zhao et al., 2009; Maeda et al., 2011). Although much progress
has been made, the etiology of AD is still unclear and hence no
preventive measure and effective disease-modifying treatment for
this disease are currently available (Citron, 2010).
Accumulated data showed that senile plaques and NTFs are
associated with the death of cholinergic neurons in AD. How-
ever, these two major pathological hallmarks might be just a
consequence of the disease process rather than an initial event
that causes AD (Huang et al., 2014). The failed result of several
major clinical trials targeting Aβ (Ayton et al., 2012) is one of the
strongest supports for this viewpoint. Doubtless, further studies
on pathophysiological mechanisms involved in the formation of
these two major pathological hallmarks in AD are fundamental
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 216 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Qian and Ke Non-cholinergic effects of huperzine A
and critical not only for elucidating the etiology of AD but also for
the development of a disease-modifying treatment for AD. Also,
further studies on the “non-cholinergic” of HupA might provide
important insights into the etiology of AD.
NON-CHOLINERGIC EFFECTS ON ALZHEIMER’S DISEASE
A number of recent studies have reported that HupA has neu-
roprotective properties, possessing both “cholinergic” and “non-
cholinergic” effects on AD. Here, we will discuss the major
non-cholinergic effects of HupA on AD.
PROTECTING NEURONS AGAINST Aβ-INDUCED OXIDATIVE INJURY
AND APOPTOSIS
Increased oxidative stress is associated with a number of neurode-
generative diseases, including AD. It has been well documented
that Aβ treatment can generate oxidative stress that eventually
triggers a state of neurotoxicity and cell death (Xiao et al., 2002).
Studies have demonstrated that HupA could enhance the cell
viability and the activities of antioxidant enzymes including glu-
tathione peroxidase (GSH-Px), superoxide dismutase (SOD), and
catalase (CAT); decrease the level of malondialdehyde (MDA) in
PC12 (neuron-like rat pheochromocytoma) cells and cultured rat
primary cortical neurons (Xiao et al., 2000a,b); and markedly
reduced the MDA level in chronic cerebral hypo-perfusion rats
(Wang et al., 2000) and aged rats (Shang et al., 1999). The protec-
tive effect of HupA on Aβ-induced cell lesion was also observed in
NG108–15 cells (Zhang et al., 2002a). These results indicate that
HupA can function as an antioxidant in Aβ-induced oxidative
stress model by increasing the activities of antioxidant enzymes.
The neuroprotective effects of HupA against Aβ-induced oxida-
tive injury are at least partly associated with its anti-apoptotic
action. There is considerable evidence showing that Aβ can acti-
vate intracellular apoptosis pathways, which lead to neuronal
death (Saille et al., 1999). Activation of caspase-3 is a key event
in the execution of apoptotic cascade in central nervous system
diseases. It has been demonstrated that HupA could attenuate
the increase of caspase-3 activity induced by Aβ in cultured pri-
mary cortical neurons (Xiao et al., 2002) and inhibit Aβ-induced
apoptosis by reversing the down-regulation of the expression of
Bcl-2 and the up-regulation of the expressions of Bax and p53
(Wang et al., 2001a). HupA had the same effects on H2O2-induced
apoptosis with a down-regulation of the bax and p53 genes and
up-regulation of the Bcl-2 gene to normal levels (Wang et al.,
2001b).
AMELIORATING MITOCHONDRIAL MALFUNCTION IN ALZHEIMER’S
DISEASE BRAIN
Perturbations in mitochondrial function have long been observed
in samples derived from clinically confirmed patients with
AD, including altered mitochondrial morphology, compromised
enzyme complexes in the tricarboxylic acid cycle, and reduced
cytochrome c oxidase activity (Cardoso et al., 2001). In addition,
accumulated evidence showed that mitochondria are direct targets
of Aβ (Yao et al., 2011). Aβ could be accumulated within mito-
chondria and interact with a mitochondrial protein, Aβbinding-
alcohol-dehydrogenase, resulting in decreased cytochrome c oxi-
dase activity and increased oxidative stress (Reddy and Beal, 2008).
The neurotoxicity induced by Aβ will trigger a vicious cycle in
which excessive Aβ accumulation and sustained mitochondrial
dysfunction synergize to activate a cascade of neurodegenerative
pathways (Silva et al., 2012).
Studies have provided evidence that HupA has the ability
to effectively ameliorate the mitochondrial malfunction. Aβ(25–
35) treatment could lead to a rapid decline of adenosine 5’-
triphosphate (ATP) level, an obvious disruption of mitochondrial
membrane homeostasis and integrity, a reduction in key enzyme
activities in the electron transport chain and the tricarboxylic
acid cycle, and an increase in intracellular reactive oxygen species
(ROS) in PC12 cells, while HupA not only attenuated these signs
of cellular stress caused by Aβ, but also enhanced ATP concen-
tration and decreased ROS accumulation (Gao and Tang, 2006).
In isolated rat brain mitochondria, HupA was able to effectively
prevent Aβ-induced mitochondrial swelling, ROS increase, and
cytochrome c release. Furthermore, it could also ameliorate Aβ-
induced decreases in mitochondrial respiration, ATP synthesis,
mitochondrial respiratory chain enzyme activity, and transmem-
brane potential (Gao et al., 2009). There is no evidence for
the existence of cholinergic system in isolated brain mitochon-
dria. Therefore, the mitochondria-targeted effects of HupA are
clearly independent of cholinergic system. In addition, HupA
could inhibit the penetration of Aβ into mitochondria and amelio-
rated Aβ-induced dysfunction of tricarboxylic acid cycle in isolated
brain cortical mitochondria (Yang et al., 2012).
ANTAGONIZING EFFECTS ON N -METHYL-D-ASPARTATE RECEPTORS
Synaptic plasticity, the variable efficacy of neurotransmission at
synapses, is thought to underlie the ability of the brain to store
memories (Martin et al., 2000). The forms of synaptic plasticity
that are most likely to be involved in memory storage require gene
transcription and protein synthesis to stabilize synaptic changes
over time (Adams and Dude, 2005). Glutamatergic synapses
mediate virtually all excitatory neurotransmission in mammalian
brains (Sucher et al., 1996). Glutamate released from presynaptic
terminals activates several types of glutamate-gated ion chan-
nels on postsynaptic membranes, includingN -methyl-d-aspartate
(NMDA) receptors (Rao and Finkbeiner, 2007). Permeability to
Ca2+ is a feature of all NMDA receptors (NMDA-R), which are
composed of an essential NR1 subunit and multiple NR2 subunits
(Rao and Finkbeiner, 2007). Excitotoxicity caused by disturbances
of glutamatergic neurotransmission in the brain has been shown
to be involved in the pathogenesis of AD (Emilien et al., 2000).
NMDA receptor antagonists have been used as neuroprotective
agents to ameliorate the cognition deficits of patients with AD
(Emilien et al., 2000; Marx, 2000).
Huperzine A could inhibit NMDA-induced toxicity in a dose-
dependent way in cultured primary neuronal cells (Marx, 2000).
HupA interacts with the NMDA ion channel by inhibition
of [3H]MK-801 and [3H]TCP binding in brain synaptosomal
plasma membranes but not the glycine or NMDA ligand-specific
sites. The non-competitive binding results suggest that HupA
inhibits the NMDA-induced toxicity most likely by blocking
NMDA ion channels and the subsequent Ca2+ mobilization at
or near the PCP and MK-801 ligand sites (Gordon et al., 2001).
HupA reversibly inhibited NMDA-induced current in acutely
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dissociated rat hippocampal pyramidal neurons and blocked spe-
cific [3H]MK-801 binding in synaptic membranes from rat cere-
bral cortex (Wang et al., 1999) and the inhibitory effect is non-
competitive (Zhang and Hu, 2001). HupA acts as antagonist of
the NMDA-R, acting at one of the polyamine binding sites on the
NMDA-R (Zhang et al., 2002b).
REGULATING THE EXPRESSION AND SECRETION OF NERVE GROWTH
FACTOR
Nerve growth factor (NGF), a neurotrophin, plays a trophic role
both during development and in adulthood (Aloe et al., 2012), and
exerts its biological action by interacting with the specific recep-
tor tropomyosin kinase receptor A (TrkA) (Huang and Reichard,
2003). Studies on rodents (Fischer et al., 1987) and primates
(Tuszynski et al., 1991) have demonstrated that exogenous NGF
was able to protect basal forebrain cholinergic neurons (BFCNs)
from both traumatic insults and age-related cholinergic decline.
Also, NGF is able to regulate both amyloid gene expression and
protein processing (Rossner et al., 1998) and to counteract tau
hyperphosphorylation (Zhang et al., 2010), acting directly at the
two classical hallmarks of AD. A decreased NGF immunoreac-
tivity in the BFCNs of patients with AD suggested that impaired
NGF supply via retrograde transport could be the effective cause
of cholinergic neurodegeneration in AD (Scott et al., 1995). These
findings plus the experimental studies on NGF deficit-induced
neurodegeneration in transgenic mice demonstrated a novel causal
link between neurotrophic signaling deficits and Alzheimer’s neu-
rodegeneration (Cattaneo and Calissano, 2012). Alteration in the
homeostasis and equilibrium of NGF processing and NGF/TrkA
signaling in target neurons has been considered as an upstream
driver of all the cellular and molecular central hallmarks of AD
(Tang et al., 2005).
Therefore, it will be very important to re-establish a correct
homeostatic balance between ligands, and receptors, of the NGF
pathway (Tang et al., 2005). Wang et al. (2006) investigated the
effects of HupA on secretion of NGF in cultured rat cortical astro-
cytes and neurite outgrowth in rat PC12 cells and demonstrated
that HupA treatment induced a significant increase in both mRNA
and protein levels of NGF in astrocytes. They also found that treat-
ment of PC12 cells with HupA led to a significant increase in the
number of neurite-bearing cells without significant alteration in
cell viability or other signs of cytotoxicity. The positive effect of
HupA on the mRNA and protein levels of NGF, accompanied by
the inhibitory effects on the memory deficits and neuronal dam-
age, have also been reported in mice treated with transient cerebral
ischemia and re-perfusion (Wang et al., 2006). These findings
suggested that HupA has a direct or indirect neurotrophic activ-
ity, which might be beneficial in treatment of neurodegenerative
disorders such as AD (Tang et al., 2005).
PROMOTING NON-AMYLOIDOGENIC AMYLOID PRECURSOR PROTEIN
PROCESSING BY ACTIVATING PROTEIN KINASE C AND THE
Wnt/β-CATENIN SIGNALING PATHWAY
The canonical Wnt signaling pathway has an important role
in development and maintenance of the nervous system and is
also associated with neurodegenerative diseases (De Ferrari et al.,
2003). Loss of Wnt signaling function is involved in Aβ-dependent
neurodegeneration in the AD brain and two key components of
the canonical Wnt signaling pathway, glycogen synthase kinase
(GSK)-3β and β-catenin, are altered in the AD model mouse brain
(Pei et al., 1999). It has also been reported that activation of Wnt
signaling can prevent neurodegeneration induced by Aβfibrils (De
Ferrari et al., 2003) and that inhibition of GSK-3β and enhance-
ment of β-catenin activity could prevent the loss of function of the
Wnt signaling pathway caused by Aβ toxicity (Farias et al., 2005).
Wang et al. (2011) showed that HupA has a role in the regu-
lation of Wnt signaling in APPswe/PS1dE9 (APP/PS1) transgenic
mouse and APPsw cell models and could significantly inhibit GSK-
3β activity and stabilize β-catenin protein level in vivo and in vitro.
They also found that HupA induced a significant increase in
the phosphorylation levels of both GSK-3α and GSK-3β proteins
in APP/PS1 mouse brain and APPsw-overexpressing cells, while
activation of both GSK-3α and GSK-3β through their autophos-
phorylation has been implicated in AD pathogenesis (Caricasole
et al., 2004). Their findings suggested that HupA can inhibit the
activity of GSK-3α/β and, hence, may inhibit Aβ generation and
tau phosphorylation. HupA reverses protein kinase C (PKC)- and
Wnt-inhibitor-induced inhibition of non-amyloidogenic process-
ing of amyloid precursor protein (APP), paralleled by an inacti-
vation of GSK-3 and a reversal of the level of β-catenin (Zhang
et al., 2004; Wang et al., 2011). These findings imply that HupA
is involved in regulation of the Wnt signaling pathway and that
HupA regulates APP processing to the non-amyloidogenic path-
way at least partly through activation of PKC and Wnt/β-catenin
signaling.
REDUCING IRON IN AD BRAIN
Misregulation in brain iron has been considered to be one of the
primary causes of neuronal death in neurodegenerative disorders
(Qian et al., 1997; Qian and Shen, 2001; Lei et al., 2012). Evidence
has also been gathered to imply that Aβ production, precipita-
tion, and toxicity in AD are caused by abnormal interactions with
neocortical iron (Zhu et al., 2004; Zhao et al., 2008; Smith et al.,
2010). In a recent study (Huang et al., 2014), we demonstrated
for the first time that HupA was able to reduce significantly the
contents of insoluble and soluble A(β-40 and A(β-42 and hyper-
phosphorylated tau in the brain of APP/PS1 transgenic mice. Also,
HupA could decrease the deposition of amyloid plaques and the
levels of oligomeric Aβ. It also suppressed APP695 expression and
increase ADAM10 contents in APP/PS1 mice brain. However, all
of these beneficial effects of HupA could be largely abolished by
high iron diet. In addition, the iron levels in the hippocampus
and cortex of the APP/PS1 mice were found to be elevated while
quantitative analysis revealed that the abnormal increase in brain
iron contents in these two regions were almost completely normal-
ized by the chronic treatment with HupA. Our findings provided
direct evidence for the inhibitory effect of HupA on brain iron,
and implied that the beneficial effects of HupA on AD is caused
by the reduction in brain iron in the APP/PS1 mice.
Furthermore, we showed that mutation of APPswe/PS1dE9
could lead to a significant increase in transferrin receptor 1
(TfR1) expression and that HupA was able to induce a signifi-
cant reduction in TfR1 expression in the brain of APP/PS1 mice
in vivo, and a remarkable reduction in TfR1 expression as well
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as transferrin-bound iron (TBI) uptake in the cultured neurons
in vitro. Two AChE inhibitors donepezil or galantamine did not
induce any changes in TfR1 expression in the brain and had no
effect on TBI uptake by the neurons, indicating that effects of
HupA on TfR1 expression and TBI uptake were independent of its
anti-AChE action. Based on the above findings, we propose that
HupA has the ability to inhibit TfR1 expression and then reduce
TBI uptake by the neurons or other brain cells, leading to a pro-
gressive reduction in iron contents and also iron-induced oxidative
stress in the brain (Huang et al., 2014).
DISEASE-MODIFYING POTENTIAL OF HUPERZINE A
Currently Hup A is proved to be used in China to improve symp-
toms of AD (Zangara, 2003). The information available from
clinical trials of Hup A was mainly on patients with mild and
moderate AD, showing significant improvement in their cognitive
functions (Rafii et al., 2011; Yang et al., 2014). However, due to
the relatively short study duration (<6 months) and lack of other
pathological assessments, it is still premature to conclude from
these trials that HupA could slow down the progress of AD. On the
other hand, studies on animal model of AD (e.g., APP/PS1 mice)
have shown that HupA could suppress Aβ accumulation, and amy-
loid plaques and hyperphosphorylated tau formation when drug
administration began at an early stage (Wang et al., 2011; Huang
et al., 2014). This result implied that HupA may be also beneficial
if taken at preclinical stage of AD. Therefore, further long-term
longitudinal clinical trials and preclinical studies are demanded in
determining the optimal time to start the treatment and monitor-
ing of disease progression. Additional studies will also be needed
to address the safety of long-term treatment.
SUMMARY
Studies on non-cholinergic roles of HupA have made important
contributions for the understanding of pharmacological mech-
anisms of HupA in the treatment of AD. In addition to the
symptomatic, cognitive-enhancing effect via cholinesterase inhi-
bition, HupA has a number of “non-cholinergic” effects on AD,
including the ability to protect neurons against Aβ-induced oxida-
tive injury and apoptosis, to ameliorate mitochondrial malfunc-
tion, to antagonize NMDA-R, to regulate NGF, promote non-
amyloidogenic APP processing, and to reduce iron in the brain
(Figure 1). Therefore, this multiplicity of action renders HupA a
FIGURE 1 | A summary of pharmacological mechanisms of huperzine A
(HupA) in the treatment of Alzheimer’s disease (AD). In addition to acting
as an acetylcholinesterase (AchE) inhibitor, HupA has non-cholinergic roles in
the treatment of AD to protect neurons and other brain cells from oxidative
stress damage and apoptosis. It has been demonstrated that HupA has the
ability: (1) to protect neurons against Aβ-induced oxidative injury and
apoptosis by enhancing the activities of antioxidant enzymes including
glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase
(CAT), attenuating the Aβ-induced increase in caspase-3 activity, and
inhibiting Aβ-induced apoptosis by reversing the down-regulation of the
expression of Bcl-2 and the up-regulation of Bax and p53 expressions; (2) to
ameliorate mitochondrial malfunction in AD brain by preventing
Aβ-penetration into the mitochondria, suppressing ROS production, and
improving mitochondrial integrity and energy metabolism, thus minimizing
Aβ-induced mitochondrial malfunction; (3) to act as antagonist of the NMDA
receptors (NMDA-R) to inhibit the NMDA-induced toxicity by blocking NMDA
ion channels and the subsequent Ca2+ mobilization; (4) to increase nerve
growth factor (NGF), which protects basal forebrain cholinergic neurons
(BFCNs) from both traumatic insults and age-related cholinergic decline and
regulate both amyloid gene expression and protein processing and
counteract tau hyperphosphorylation, acting directly at the two classical
hallmarks of AD; (5) to promote non-amyloidogenic processing by activating
protein kinase C (PKC) and the Wnt/β-catenin signaling pathway; and (6) to
inhibit transferrin receptor 1 (TfR1) expression and then reduce
transferrin-bound iron (TBI) uptake by the neurons or other brain cells, which
have TfR1 expression on the membrane, leading to a progressive reduction
in iron contents and also iron-induced oxidative stress in the brain. Based on
these roles, it is reasonable to consider HupA as an effective
disease-modifying drug for AD. (+)= stimulate; (−)= inhibit; ↑= increase;
↓=decrease; Ach= acetylcholine.
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highly effective drug and potentially it could serve as a disease-
modifying drug for AD. It may also be used for the treatment
of other neurodegenerative disorders although further studies are
needed.
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